ISCOOTCPharmaceutical PreparationsFiscal year ends December 31
International Stem Cell CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.28+0.00 (+0.89%)
Close on Oct 19, 2026
- Market cap
- $2.27M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.1330 (+88.67%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
International Stem Cell CORP grew revenue 3.4% to $9.51M over the twelve months to Jun 30, 2026. Free cash flow was $333.00K, up 851.4% from a year earlier.
Revenue
$9.51M
+3.4% vs. a year earlier
Operating income
-$444.00K
TTM Q2 2026
Free cash flow
$333.00K
+851.4% vs. a year earlier
EPS, diluted
-$0.08
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.27M
- P/E ratio
- –
- Price to sales
- 0.24
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 14.70%
Fundamentals
- Revenue
- $9.51M
- Net income
- -$582.00K
- EPS, diluted
- -$0.08
- Free cash flow
- $333.00K
- Book value per share
- -$0.53
- Diluted shares
- 8M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$9.51M+3.4% YoY
Gross profit
$5.23M-1.7% YoY
Operating income
-$444.00K
Net income
-$582.00K
EPS, diluted
-$0.08
Free cash flow
$333.00K+851.4% YoY
Reported periodTrailing twelve months